© 2025 HSP News Service, L.L.C.
New research examining whether patients with ovarian cancer were receiving care concordant with the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) found clear disparities based on patients’ race, ability to pay, and access to specialists and...
On November 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere) for adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received...
To achieve its goal of eliminating cervical cancer, the World Health Organization (WHO) is calling on all countries “to reach and maintain an incidence rate of below 4 per 100,000 women.” Doing so would depend on the following: A total of 90% of girls being fully vaccinated against human...
Researchers discovered a differential clinical response to pembrolizumab in patients with Lynch-like (mutated) vs methylated microsatellite instability–high endometrial cancer, outlining characteristics of patients who may derive benefit from immune checkpoint blockade antibodies, according to new...
In a study reported in the Journal of Clinical Oncology, Benoit You, MD, PhD, and colleagues found that an unfavorable CA-125 elimination rate constant K (KELIM) score, indicating poorer tumor chemosensitivity, was associated with derived benefit from first-line bevacizumab when given with...
Researchers have developed a new swab test that can identify origins of potentially dangerous cervical cell changes up to 4 years before they happen, according to a new study published by Barrett et al in Genome Medicine. Scientists found that the new cervical screening method was more sensitive...
A new study has found that sexual side effects of cancer treatment are discussed far less frequently with female patients than with male patients, even when the treatment directly affects sex organs. Among patients receiving brachytherapy for prostate or cervical cancer at a high-volume cancer...
Individuals who reported using chemical hair-straightening products may be at greater risk for uterine cancer compared to those who did not report using these products, according to a new study published by Chang et al in the Journal of the National Cancer Institute (JNCI). The researchers found no ...
Studies show that rural populations experience greater cancer disparities across the cancer control continuum—from prevention and incidence to survivorship and mortality—compared with their urban counterparts. Those living in rural parts of the United States also tend to have lower cancer screening ...
Populations in U.S. counties defined as more vulnerable based on social factors—including socioeconomic status and racial and ethnic minority status—may be significantly less likely to receive timely breast, cervical, and colorectal cancer screenings, according to a recent study published by Bauer...
In a phase II trial reported in the Journal of Clinical Oncology, Panagiotis A. Konstantinopoulos, MD, PhD, and colleagues found that letrozole plus abemaciclib produced activity in patients with estrogen receptor (ER)-positive recurrent endometrial cancer. Study Details In the study, 30 patients...
Jonathan Ledermann, MD, of UCL Cancer Institute University College London, was the formal discussant of both the phase III SOLO1 and PAOLA-1 trials. He was quite enthusiastic about SOLO1: “Perhaps, this is really cure we are seeing.” He also noted that overall survival is still immature and is...
First-line maintenance therapy with olaparib extended survival beyond historical expectations in some women with newly diagnosed advanced ovarian cancer, according to two phase III studies presented at the European Society for Medical Oncology (ESMO) 2022 Congress.1,2 In the SOLO1 trial,1 more...
In a case-control study within the U.S. Women’s Health Initiative (WHI) study population reported in JAMA Oncology, Lønning et al found that BRCA1 promoter methylation identified in white blood cells was associated with increased risks of incident triple-negative breast cancer and high-grade serous ...
As reported in the Journal of Clinical Oncology by DiSilvestro et al, the 7-year follow-up of the phase III SOLO1/GOG 3004 trial showed a reduction in risk of death by almost half with maintenance olaparib vs placebo in newly diagnosed patients with advanced ovarian cancer and a BRCA1/2 mutation,...
In a phase III trial reported in the Journal of Clinical Oncology, Janos L. Tanyi, MD, PhD, and colleagues found that use of pafolacianine infusion for intraoperative imaging improved the detection of lesions in patients with folate receptor–positive ovarian cancer, compared with using white light...
Ana Oaknin, MD, PhD, of Barcelona’s Vall d’Hebron University Hospital, discusses findings from the CheckMate 358 trial, which showed that chemotherapy-free immunotherapy with nivolumab alone or in combination with ipilimumab may provide durable tumor regression with manageable toxicity in patients with recurrent or metastatic cervical cancer, regardless of tumor PD-L1 expression (Abstract 520MO).
Ana Oaknin, MD, PhD, of Barcelona’s Vall d’Hebron University Hospital, discusses an analysis of long-term survival from the EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial. Cemiplimab-rwlc is the first immunotherapy to demonstrate an overall survival benefit as a second-line monotherapy for patients with recurrent or metastatic cervical cancer previously treated with platinum-based chemotherapy but not immunotherapy. The benefit was sustained in this population (Abstract 519MO).
Paul A. DiSilvestro, MD, of Women & Infants Hospital and the Warren Alpert Medical School of Brown University, discusses overall survival results after a 7-year follow-up of the SOLO1/GOG-3004 trial for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation who received maintenance olaparib. Dr. DiSilvestro details the increasing role of such PARP inhibitors in ovarian cancer treatment and their benefit to patients (Abstract 517O).
On August 11, 2022, Roche announced the U.S. Food and Drug Administration (FDA) approval of a label expansion for the Ventana MMR RxDx Panel. The Ventana MMR RxDx Panel is the first immunohistochemistry companion diagnostic test to aid in identifying patients whose solid tumors are deficient in DNA ...
As reported in the Journal of Clinical Oncology, Herzog et al have developed a simple noninvasive test for screening for suspected endometrial cancer—the Women’s Cancer Risk Identification-Quantitative Polymerase Chain Reaction Test for Endometrial Cancer (WID-qEC)—that has shown accuracy in...
In an Australian population–based study reported in the Journal of Clinical Oncology, Spilsbury et al found that perioperative dispensing of nonselective beta-blockers was associated with improved survival among patients with a history of a cardiovascular condition undergoing surgery for epithelial ...
As reported in the Journal of Clinical Oncology by Yeung et al, updated results of the phase III NRG Oncology RTOG 1203 trial show reduced chronic toxicity with adjuvant intensity-modulated radiation therapy (IMRT) vs conventional radiotherapy (CRT) in women with cervical or endometrial cancer. No...
The steepest annual rise in new cases of advanced cervical cancer in the United States from 2001 to 2018 was among White patients, who were significantly less likely to receive the preventive human papillomavirus (HPV) vaccine or to be screened for the disease, according to research published by...
On August 11, Roche announced the U.S. Food and Drug Administration (FDA) approval of a label expansion for the Ventana MMR RxDx Panel. The Ventana MMR RxDx Panel is the first immunohistochemistry (IHC) companion diagnostic test to aid in identifying patients whose solid tumors are deficient in DNA ...
Giving women the human papillomavirus (HPV) vaccine around the time they have surgery for precancerous cervical lesions might lead to a reduction in the risk of lesions returning as well as other HPV-related diseases, suggests a study published by Kechagias et al in The BMJ. The researchers...
In a phase II trial reported in JAMA Oncology, Konstantinopoulos et al found that the combination of talazoparib and avelumab was active in patients with recurrent mismatch repair–proficient endometrial cancer. Study Details In the U.S. multicenter study, 35 evaluable women with measurable disease, ...
In an individual-level meta-analysis reported in the Journal of Clinical Oncology, Hurwitz et al found that frequent aspirin use was associated with reduced risk of ovarian cancer, including high-grade serous ovarian cancer and among women with multiple risk factors. Study Details The analysis...
Frequent aspirin use may be linked with lower ovarian cancer risk in individuals with multiple risk factors, according to a new study published by Hurwitz et al in the Journal of Clinical Oncology. “Ovarian cancer is the most fatal gynecologic cancer. Most known risk factors of ovarian cancer—such...
In an Italian/French trial (TOTEM) reported in the Journal of Clinical Oncology, Zola et al found no difference in 5-year overall survival with intensive vs minimalist follow-up regimens in patients in complete clinical remission after surgery for endometrial cancer. Study Details In the...
In a systematic review and network meta-analyses reported in The Lancet Oncology, Athanasiou et al described the comparative effectiveness of and risk of preterm birth with local excisional and ablative treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer. Study Details...
Researchers have discovered that a protein associated with metabolism—and formerly recognized as a potential therapeutic target for ovarian cancer—may instead be associated with a better prognosis for patients with the malignancy. In a report published by Clemente et al in Cancer Research...
Telling children about their mother’s risk of hereditary breast and/or ovarian cancer does not adversely influence the offspring’s lifestyle or quality of life in the long term, according to a new study published by McDonnell et al in the journal Pediatrics. The study looked at the mutation status...
Bradley J. Monk, MD, of the University of Arizona College of Medicine and Creighton University School of Medicine, discusses phase III findings from the ATHENA–MONO (GOG-3020/ENGOT-ov45) trial. It showed that rucaparib as first-line maintenance treatment, following first-line platinum-based chemotherapy, improved progression-free survival in patients with ovarian cancer, irrespective of homologous recombination deficiency status (Abstract LBA5500).
In a systematic review and meta-analysis reported in The Lancet Oncology, Arbyn et al found that the performance of a high-risk human papillomavirus (hrHPV) mRNA test in screening for cervical cancer was similar to that of validated hrHPV DNA tests in detection of cervical intraepithelial neoplasia ...
As reported in the Journal of Clinical Oncology by Copeland et al, the phase III Gynecologic Oncology Group 0212/NRG Oncology study has shown no improvement in overall survival with maintenance paclitaxel or paclitaxel poliglumex vs surveillance in patients with advanced ovarian, tubal, or...
Invited discussant Ernst Lengyel, MD, PhD, of University of Chicago Medicine, found the results of ATHENA-MONO promising. “I think it is encouraging that in the BRCA-mutation subgroup of patients, we see such a clear increase in progression-free survival compared to the intention-to-treat...
Maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib led to a significant improvement in progression-free survival compared with placebo in patients with newly diagnosed advanced ovarian cancer who responded to first-line platinum-based chemotherapy. The...
In March 2022, Kristeleit et al reported the results of the ARIEL4 trial1 of rucaparib in relapsed BRCA-mutant ovarian cancer in The Lancet Oncology (summarized in this issue of The ASCO Post) and are to be congratulated on this accomplishment. This report, along with the almost simultaneous...
As reported in The Lancet Oncology by Rebecca Kristeleit, MD, of Guy’s and St. Thomas’ NHS Foundation Trust, and colleagues, the phase III ARIEL4 trial has shown a statistically significant improvement in progression-free survival with rucaparib vs chemotherapy in relapsed ovarian cancer with...
In an analysis from an NRG Oncology/Gynecologic Oncology Group phase II study (GOG-86P) reported in the Journal of Clinical Oncology, Thiel et al looked at outcomes in patients with advanced endometrial cancer treated with bevacizumab added to front-line chemotherapy. The investigators found that...
As reported in The Lancet Oncology by Andrew R. Clamp, PhD, and colleagues, no significant differences in overall survival or updated progression-free survival were found with first-line treatment with weekly dose-dense regimens of carboplatin/paclitaxel vs every-3-week carboplatin/paclitaxel in...
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Domenica Lorusso, MD, PhD, of Italy’s Gemelli University Hospital, discuss phase III data from the MITO23 trial on single-agent trabectedin vs clinician’s choice of chemotherapy in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype. Although trabectedin has demonstrated antitumor activity in relapsed platinum-sensitive disease, it does not appear to improve survival outcomes when compared with standard chemotherapy in the BRCA-mutated population (Abstract LBA5504).
As reported in The New England Journal of Medicine by Krishnansu S. Tewari, MD, of the Division of Gynecologic Oncology, University of California, Irvine, and colleagues, the phase III EMPOWER-Cervical1/GOG-3016/ENGOT-cx9 trial has shown improved overall survival with cemiplimab-rwlc vs...
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Ignace Vergote, MD, PhD, of Belgium’s University Hospitals Leuven, discuss interim safety and efficacy results from a third dose-expansion cohort evaluating first-line tisotumab vedotin-tftv plus pembrolizumab in patients with recurrent or metastatic cervical cancer. Data on the combination showed durable antitumor activity with a manageable safety profile (Abstract 5507).
As presented at the 2022 ASCO Annual Meeting (Abstract LBA5500) and simultaneously reported in the Journal of Clinical Oncology by Bradley J. Monk, MD, and colleagues, the phase III ATHENA-MONO trial found that maintenance rucaparib significantly improved progression-free survival vs placebo among...
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Nicoletta Colombo, MD, of the University of Milan and the European Institute of Oncology, discuss phase II results on the overall survival benefit of intermittent relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel, compared with nab-paclitaxel alone in patients with recurrent platinum-resistant ovarian cancer. A phase III trial comparing intermittent relacorilant plus nab-paclitaxel with investigator’s choice of chemotherapy in primary platinum-refractory disease is ongoing (Abstract LBA5503).
Benoit You, MD, PhD, of Lyon University hospital (HCL, France) and GINECO group (France), discusses findings from the GOG-0218 trial of patients with ovarian cancer, which appears to confirm earlier data on the link between poor tumor chemosensitivity and benefit from concurrent plus maintenance bevacizumab. In Dr. You’s validation study, patients who derived the most progression-free and overall survival benefit from bevacizumab were those with high-risk disease (stage IV or incompletely resected stage III) associated with an unfavorable KELIM score (CA-125 kinetic elimination rate constant, calculable online) (Abstract 5553).
A triplet regimen consisting of the PARP (poly [ADP-ribose] polymerase) inhibitor olaparib, metronomic (the chronic administration of low, equally spaced doses of) cyclophosphamide, and metformin demonstrated activity in elderly, heavily pretreated patients with recurrent, advanced endometrial...
In a French phase I/II trial (VICTORIA) reported in JAMA Oncology, Heudel et al found that the addition of the mTOR inhibitor vistusertib to anastrozole improved outcomes in women with hormone receptor–positive recurrent or metastatic endometrial cancer. As stated by the investigators, “Endometrial ...